A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients with Advanced Malignancies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Malignancies
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    To participate in the study the following conditions must be met:
    1. Diagnosed with solid tumors that have come back, spread to nearby tissues, or have spread to other parts of the body.
    2. Tumors must be located in a place where a biopsy (removal of a small piece of tissue for examination) can be done with an acceptable level of risk, as determined by the doctor in charge of the study. Patients must also give their consent to have biopsies done before and during the treatment. For patients who don't meet these criteria, biopsies are optional.
    3. 3) Patient's disease must have gotten worse, as confirmed by X-rays, clinical exams, or tissue samples, while they were receiving their most recent cancer treatment or after they finished it.

You may not be eligible for this study if the following are true:

  • You will not be able to participate in the study if you have had:
    1. A history of severe allergic reactions to other monoclonal antibodies (mAbs).
    2. Any previous treatment with a medication called anti-ILT4 monoclonal antibody (mAb) therapy.
    3. Received more than one targeted therapy called anti-PD-1 or anti-PD-L.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.